Kiniksa Pharmaceuticals International, plc
KNSA
$47.02
$0.521.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 259.75% | 245.24% | 556.29% | 148.23% | -135.22% |
| Total Depreciation and Amortization | 16.75% | -3.76% | -16.74% | -25.97% | -25.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 98.68% | 256.42% | -37.67% | -6.37% | 138.43% |
| Change in Net Operating Assets | 25.99% | -118.15% | 83.19% | -81.36% | 618.48% |
| Cash from Operations | 187.13% | 1,606.13% | 443.54% | 459.92% | 333.99% |
| Capital Expenditure | -227.98% | -- | -- | -17.86% | -244.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -207.17% | -878.01% | 92.06% | -300.88% | 541.34% |
| Cash from Investing | -208.46% | -888.58% | 91.70% | -301.93% | 538.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 215.29% | 72.88% | 1,022.91% | -20.38% | 184.22% |
| Repurchase of Common Stock | -58.82% | -60.51% | -55.90% | -8.14% | -120.61% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 257.52% | 77.89% | 6,110.11% | -23.39% | 208.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.74% | -806.54% | 183.49% | -179.85% | 973.05% |